Background
Phase 3, open-label, randomized controlled trial (CLL17). N=926 treatment-naive CLL patients, all-comers including fit and unfit. Randomized 1:1:1 to continuous ibrutinib (I), fixed-duration venetoclax + ibrutinib (VenI, 15 months), or fixed-duration venetoclax + obinutuzumab (VenO, 15 months). Primary endpoint: PFS at 3 years. Head-to-head trial of three modern non-chemotherapy regimens. Published NEJM December 2025.
Interventions and follow up
Arm A: Ibrutinib 420 mg PO daily until progression or unacceptable toxicity (continuous)
Arm B: Venetoclax (ramp-up to 400 mg) + ibrutinib 420 mg PO daily × 15 months (fixed-duration VenI)
Arm C: Venetoclax + obinutuzumab 1000 mg IV per cycle × 15 months (fixed-duration VenO)
Primary endpoint: 3-year PFS (each fixed-duration arm vs ibrutinib; non-inferiority then superiority)
Median follow-up: ~36 months
Arm B: Venetoclax (ramp-up to 400 mg) + ibrutinib 420 mg PO daily × 15 months (fixed-duration VenI)
Arm C: Venetoclax + obinutuzumab 1000 mg IV per cycle × 15 months (fixed-duration VenO)
Primary endpoint: 3-year PFS (each fixed-duration arm vs ibrutinib; non-inferiority then superiority)
Median follow-up: ~36 months
Results
3-yr PFS (VenO): 81.0%
3-yr PFS (VenI): 79.4%
3-yr PFS (ibrutinib): 81.1%
Non-inferiority: Both VenO and VenI non-inferior to ibrutinib
uMRD4 (peripheral blood) — VenO vs VenI vs ibrutinib: 57% vs 53% vs 4%
ORR: ~97% across all arms
3-yr PFS (VenI): 79.4%
3-yr PFS (ibrutinib): 81.1%
Non-inferiority: Both VenO and VenI non-inferior to ibrutinib
uMRD4 (peripheral blood) — VenO vs VenI vs ibrutinib: 57% vs 53% vs 4%
ORR: ~97% across all arms
Adverse events
Cardiovascular (ibrutinib): AFib any grade 15%, hypertension grade ≥3 16%, major hemorrhage 6%
Hematologic / infusion (VenO): Grade ≥3 neutropenia 44%, infusion-related reactions 46% (obinutuzumab), fewer cardiac events than ibrutinib
Tumor lysis: Clinical TLS 1% (VenI), 2% (VenO)
Discontinuation due to AEs: ~25% with ibrutinib at 3 years; overall grade ≥3 AEs similar across arms
Hematologic / infusion (VenO): Grade ≥3 neutropenia 44%, infusion-related reactions 46% (obinutuzumab), fewer cardiac events than ibrutinib
Tumor lysis: Clinical TLS 1% (VenI), 2% (VenO)
Discontinuation due to AEs: ~25% with ibrutinib at 3 years; overall grade ≥3 AEs similar across arms
Conclusions
Fixed-duration VenO and VenI achieved 3-year PFS non-inferior to continuous ibrutinib in treatment-naive CLL, with significantly higher uMRD rates (~57% and 53% vs 4%). Fixed-duration regimens offer a chemotherapy-free, time-limited option with high MRD negativity and avoid the cumulative toxicity of indefinite BTKi therapy.
Key Limitations
~3-year follow-up is likely insufficient to detect late PFS divergence, particularly for IGHV-mutated patients. The non-inferiority design means fixed-duration arms are not proven superior to ibrutinib for PFS. High uMRD rates do not guarantee superior long-term outcomes versus continuous therapy; retreatment data after VenO/VenI relapse are limited. Neither VenI nor VenO frontline combination is FDA-approved (as of 2025), with approvals pending. IGHV subgroup analyses warrant attention for treatment selection.
Clinical Context
CLL17 is a landmark trial establishing non-inferiority of fixed-duration, chemotherapy-free doublets to continuous ibrutinib in frontline CLL. Together with GLOW and CLL13/GAIA, it supports fixed-duration venetoclax-based combinations as standard alternatives to continuous BTKi. It positions VenO similarly to CLL14 (venetoclax + obinutuzumab) but with a BTKi comparator. Pending FDA approval for frontline VenO/VenI, zanubrutinib + venetoclax (CLL13) and ibrutinib + venetoclax (CAPTIVATE, GLOW) remain options. ESMO-MCBS: not yet assigned.